Diuretic

Despite dapagliflozin not improving diuretic efficiency in the setting of acute HF hospitalization, it was associated with fewer diuretic doses to achieve the same weight change as usual care and shorter hospital stay, researchers reported.

Adding a diuretic to renin-angiotensin system inhibitor therapy lowered the risk for disease progression in patients with chronic kidney disease compared with using a calcium channel blocker, according to study data.

Renal denervation lowered blood pressure out to 36 months, regardless of baseline antihypertensive class combinations and polypharmacy burden, according to an analysis of the Global SYMPLICITY Registry DEFINE.

CHICAGO — In this Healio exclusive, Manesh R. Patel, MD, FACC, FAHA, FSCAI, provides his perspective on a few of the late-breaking clinical trials presented at the American Heart Association Scientific Sessions.

CHICAGO — Among older veterans with hypertension, there was no difference in the incidence of major adverse CV events after treatment with hydrochlorothiazide compared with chlorthalidone, according to new research.

CHICAGO — A treatment strategy of torsemide vs. furosemide did not improve long-term clinical outcomes for adults hospitalized with HF, including all-cause mortality and all-cause hospitalization, researchers reported.

In patients with HF with reduced ejection fraction, worsening HF, defined as HF hospitalization or urgent need for IV diuretics, was independently associated with poor long-term prognosis, researchers reported.

IV acetazolamide or placebo for decongestion in patients with acute decompensated HF on loop diuretics.

In the ADVOR trial, the addition of IV acetazolamide to standard IV loop diuretics improved acute congestion at 3 days in nearly 50% more patients vs. placebo in the setting of acute decompensated HF and volume overload.

According to published data, diuretic use, dosing and monitoring varies in United States hemodialysis practice.